Phathom Pharmaceuticals (PHAT) Expected to Release Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is projected to announce its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect the company to post earnings of $0.07 per share and revenue of $84.82 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Performance

Shares of Phathom Pharmaceuticals stock opened at $5.99 on Wednesday. Phathom Pharmaceuticals has a 52-week low of $5.01 and a 52-week high of $18.31. The company’s 50 day moving average price is $7.82 and its 200-day moving average price is $10.61.

Analyst Ratings Changes

PHAT has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and set a $26.00 price target on shares of Phathom Pharmaceuticals in a report on Friday, July 31st. Needham & Company LLC cut their price target on shares of Phathom Pharmaceuticals from $28.00 to $22.00 and set a “buy” rating on the stock in a report on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a report on Thursday, October 15th. Jefferies Financial Group restated a “buy” rating and issued a $16.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday, October 14th. Finally, Craig Hallum restated a “buy” rating and issued a $15.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday, October 21st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Phathom Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $20.11.

Phathom Pharmaceuticals Company Profile

Phathom Pharmaceuticals, Inc (NASDAQ: PHAT) is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases. The company’s principal product is Voquezna (vonoprazan), a potassium-competitive acid blocker designed to suppress stomach acid through a mechanism distinct from traditional proton pump inhibitors.

In the United States, Voquezna is approved for the treatment of Helicobacter pylori infection in combination with antibiotics and for certain forms of gastroesophageal reflux disease (GERD), including erosive esophagitis and heartburn associated with non-erosive GERD.